The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aprepitant | The serum concentration of Mestranol can be decreased when it is combined with Aprepitant. |
| Exenatide | Exenatide can cause a decrease in the absorption of Mestranol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thalidomide | Mestranol may increase the thrombogenic activities of Thalidomide. |
| Mifepristone | The serum concentration of Mestranol can be increased when it is combined with Mifepristone. |
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Mestranol. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Mestranol. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mestranol. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Mestranol. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mestranol. |
| Lenalidomide | Mestranol may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Mestranol is combined with Ospemifene. |
| Ropinirole | Mestranol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Cetuximab | Mestranol may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Mestranol may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Mestranol may increase the thrombogenic activities of Omalizumab. |
| Gemtuzumab ozogamicin | Mestranol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Mestranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Trastuzumab | Mestranol may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Mestranol may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Mestranol may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Mestranol may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Mestranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Mestranol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Mestranol may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Mestranol may increase the thrombogenic activities of Alemtuzumab. |
| Efalizumab | Mestranol may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Mestranol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Mestranol may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Mestranol may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Mestranol may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Mestranol may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Mestranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Mestranol may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Mestranol may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Mestranol may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Mestranol may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Mestranol may increase the thrombogenic activities of Pexelizumab. |
| Epratuzumab | Mestranol may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Mestranol may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Mestranol may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Mestranol may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Mestranol may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Mestranol may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Mestranol may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Mestranol may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Mestranol may increase the thrombogenic activities of Bavituximab. |
| CR002 | Mestranol may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Mestranol may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Mestranol may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Mestranol may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Mestranol may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Mestranol may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Mestranol may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Mestranol may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Mestranol may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Mestranol may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Mestranol may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Mestranol may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Mestranol may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Mestranol may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Mestranol may increase the thrombogenic activities of Ustekinumab. |
| PRO-542 | Mestranol may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Mestranol may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Mestranol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Mestranol may increase the thrombogenic activities of RI 624. |
| Stamulumab | Mestranol may increase the thrombogenic activities of MYO-029. |
| CT-011 | Mestranol may increase the thrombogenic activities of CT-011. |
| Leronlimab | Mestranol may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Mestranol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Mestranol may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Mestranol may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Mestranol may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Mestranol may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Mestranol may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Mestranol may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Mestranol may increase the thrombogenic activities of Lumiliximab. |
| Ipilimumab | Mestranol may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Mestranol may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Mestranol may increase the thrombogenic activities of Clenoliximab. |
| BIIB015 | Mestranol may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Mestranol may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Mestranol may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Mestranol may increase the thrombogenic activities of Elotuzumab. |
| Carotuximab | Mestranol may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Mestranol may increase the thrombogenic activities of XmAb 2513. |
| Lucatumumab | Mestranol may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Mestranol may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Mestranol may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Mestranol may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Mestranol may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Mestranol may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Mestranol may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Mestranol may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Mestranol may increase the thrombogenic activities of Reslizumab. |
| Teplizumab | Mestranol may increase the thrombogenic activities of Teplizumab. |
| Catumaxomab | Mestranol may increase the thrombogenic activities of Catumaxomab. |
| Mepolizumab | Mestranol may increase the thrombogenic activities of Mepolizumab. |
| Denosumab | Mestranol may increase the thrombogenic activities of Denosumab. |
| Volociximab | Mestranol may increase the thrombogenic activities of Volociximab. |
| Ofatumumab | Mestranol may increase the thrombogenic activities of Ofatumumab. |